Advertisement

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

The clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. There are two reasons for Ziopharm's climb. First, it's a reaction to hitting its 52-week low as investors saw a potential bargain.